研究单位：[1]Cstone Pharmaceuticals[2]Pfizer[3]Guangdong Provincial People's hospital,Guangzhou,Guangdong,China,510080[4]Beijing Cancer Hospital,Beijing,China[5]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China[6]The First Hospital of Jilin University,Changchun,China[7]Hunan Cancer Hospital,Changsha,China[8]Sichuan Cancer Hospital & Institute,Chengdu,China[9]West China Hospital of Sichuan University,Chengdu,China[10]Chinese PLA Army Medical Center,Chongqing,China[11]Fujian Cancer Hospital,Fuzhou,China[12]Sun Yat-sen University Cancer Center,Guangzhou,China[13]The first Affiliated hospital, Sun Yat-Sen University,Guangzhou,China[14]Zhejiang Cancer Hospital,Hangzhou,China[15]Harbin Medical University Cancer Hospital,Harbin,China[16]The First Affiliated Hospital of Anhui Medical University,Hefei,China[17]Shandong Cancer Hospital&Institute,Jinan,China[18]Yunnan Cancer Hospital,Kunming,China[19]The First Affiliated Hospital of Nanchang University,Nanchang,China[20]The Second Affiliated Hospital of Nanchang University,Nanchang,China[21]Jiangsu Province Hospital,Nanjing,China[22]Fudan University Shanghai Cancer Center,Shanghai,China[23]Shanghai Pulmonary Hospital,Shanghai,China[24]Liaoning Cancer Hospital and Institute,Shenyang,China[25]Shanxi Cancer hospital,Taiyuan,China[26]Tianjin Medical University Cancer Institute & Hospital,Tianjin,China[27]The 1st Affiliated hospital of Wenzhou Medical University,Wenzhou,China[28]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China[29]Tangdu Hospital of The fourth Military Medical University Peoples Liberation Army of China,Xi'an,China[30]Xiamen Humanity Hospital,Xiamen,China[31]Henan Cancer Hospital,Zhengzhou,China[32]Henan Provincial People's Hospital,Zhengzhou,China[33]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China
研究目的：
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China
